title: [Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].
abstract: Lung cancer is a frequently occurring disease, particularly in the elderly; however, within the last 10 years the pharmaceutical treatment of lung cancer has been significantly improved. Due to a better understanding of the pathophysiological events and the identification of molecular subgroups of lung tumors, new therapeutic drugs have been developed that significantly prolong survival of patients with the respective molecular pattern. In particular immunotherapeutic agents, such as programmed death-ligand 1 (PD-L1) and programmed death 1 (PD1) antibodies have shown promising clinical results in a subgroup of lung cancer patients. Due to the high incidence of both lung cancer and rheumatic diseases they often occur together, which necessitates an interdisciplinary management. The success of improved therapy of lung cancer has led to a greater focus on the treatment of comorbidities; however, interventions into the immune system by immune checkpoint inhibitors can lead to new challenges when an autoimmune disease is simultaneously present. The possibility of an effective screening for lung cancer in the future also presents the prospect of an improvement in mortality, which raises the question of the optimal monitoring of patients with rheumatoid arthritis (RA) under immunosuppressive therapy. The aim of this review is to discuss the interaction between lung cancer and RA with respect to the currently available data.
authors.affiliation: Klinik I für Innere Medizin, Universitätsklinik Köln, Kerpenerstr. 62, 50924, Köln, Deutschland. andrea.rubbert@uk-koeln.de.
authors.forename: A
authors.initials: A
authors.lastname: Rubbert-Roth
authors.affiliation: Klinik I für Innere Medizin, Universitätsklinik Köln, Kerpenerstr. 62, 50924, Köln, Deutschland.
authors.forename: T
authors.initials: T
authors.lastname: Zander
authors.affiliation: Südstadtklinikum Rostock, Rostock, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Kneitz
authors.affiliation: Sektion Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Baerwald
authors.affiliation: Abteilung Pneumologie, Universitätsklinikum Leipzig, Leipzig, Deutschland.
authors.forename: H
authors.initials: H
authors.lastname: Wirtz
authors.affiliation: Arbeitsbereich Pneumologische Onkologie, Charité-Universitätsmedizin Berlin, Berlin, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Witt
mesh_terms: D000465:Algorithms; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology*; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D010348:Patient Care Team; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents
keywords: Autoimmune disease; Biologics; Immunosuppression; Immunotherapy; Interdisciplinary management
references.citation: Rheumatology (Oxford). 2013 Jan;52(1):91-8
references.pmid: 23238979
references.citation: Ann Rheum Dis. 2010 Jan;69(1):54-60
references.pmid: 19151010
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3552-9
references.pmid: 18506026
references.citation: J Clin Oncol. 2013 May 20;31(15):1858-65
references.pmid: 23589544
references.citation: N Engl J Med. 2010 Jun 24;362(25):2380-8
references.pmid: 20573926
references.citation: N Engl J Med. 2014 Dec 4;371(23):2167-77
references.pmid: 25470694
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5216-22
references.pmid: 17114654
references.citation: Ann Rheum Dis. 2013 Jan;72(1):79-82
references.pmid: 22945500
references.citation: Pneumologie. 2010 Mar;64 Suppl 2:e1-164
references.pmid: 20217630
references.citation: Am J Respir Crit Care Med. 2015 Jan 1;191(1):19-33
references.pmid: 25369325
references.citation: Arthritis Rheum. 2011 Jul;63(7):1812-22
references.pmid: 21305513
references.citation: Chin Clin Oncol. 2014 Sep;3(3):31
references.pmid: 25841457
references.citation: RMD Open. 2016 May 10;2(1):e000213
references.pmid: 27252893
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168
references.citation: Lung Cancer. 2015 Oct;90(1):1-7
references.pmid: 26275476
references.citation: Arthritis Res Ther. 2010;12(1):R5
references.pmid: 20064207
references.citation: J Thorac Dis. 2015 Apr;7(Suppl 2):S156-62
references.pmid: 25984362
references.citation: Arthritis Res Ther. 2008;10(2):R45
references.pmid: 18433475
references.citation: J Rheumatol. 2015 Oct;42(10):1761-6
references.pmid: 26276965
references.citation: Ann Rheum Dis. 2009 Dec;68(12):1819-26
references.pmid: 19054822
references.citation: Expert Opin Drug Saf. 2015 Jan;14 (1):97-110
references.pmid: 25345687
references.citation: N Engl J Med. 2015 Jul 9;373(2):123-35
references.pmid: 26028407
references.citation: Ann Rheum Dis. 2015 Jun;74(6):1087-93
references.pmid: 24685910
references.citation: N Engl J Med. 2011 Aug 4;365(5):395-409
references.pmid: 21714641
references.citation: Lancet Oncol. 2012 Mar;13(3):247-55
references.pmid: 22341744
references.citation: Am J Respir Crit Care Med. 2000 Jan;161(1):5-8
references.pmid: 10619790
references.citation: Lung Cancer. 2014 Feb;83(2):231-9
references.pmid: 24332320
references.citation: J Rheumatol. 2015 Aug;42(8):1368-75
references.pmid: 26034149
references.citation: Lung Cancer. 2013 Jul;81(1):142-3
references.pmid: 23558310
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: Lancet Oncol. 2011 Feb;12(2):175-80
references.pmid: 21277552